Skip to main content
main-content

Cardiovascular outcomes

News

07-10-2018 | Canagliflozin | News

CANVAS analysis supports canagliflozin CV benefit at low renal function

A secondary analysis of the CANVAS trial supports the beneficial cardiovascular and renal effects of sodium-glucose cotransporter 2 inhibition down to a low level of kidney function.

07-04-2018 | Heart failure | News

Heart failure particularly high risk in type 1 diabetes patients

The likelihood of dying during or soon after heart failure hospitalization is higher among patients with type 1 than type 2 diabetes, report researchers.

06-25-2018 | Cardiovascular outcomes | ADA 2018 | News

High risk with earlier diabetes onset seen in older population

Analysis of the Health and Retirement Study indicates that the adverse effects of earlier age of type 2 diabetes onset are also evident in an older population.

Read more

Opinion

11-22-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

11-13-2017 | Specific populations | Interview | Video

Women and diabetes - our right to a healthy future

Editorial Board member Lori Berard addresses 2017's World Diabetes Day theme, providing her insights on the key considerations for managing diabetes in women in this interview with Medicine Matters diabetes.

10-23-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.

In depth

10-17-2017 | Glucagon-like peptide-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

08-22-2017 | Canagliflozin | Podcast | Audio

Dissecting the CANVAS trial

Listen to CANVAS investigators Carol Wysham and Lori Berard discussing the efficacy and safety findings of the trials (11:17).

Journal articles and book chapters

06-22-2018 | Hypertension | Review | Article

The optimal blood pressure target in diabetes mellitus: A quest coming to an end?

Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

06-16-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

06-16-2018 | Cardiovascular disorders | Review | Article

Inpatient glycemic management of non-cardiac CVD: Focus on stroke and PVD

Everett E, Mathioudakis N. Curr Diab Rep 2018; 18: 49. doi: 10.1007/s11892-018-1026-0

image credits